Update on GSK Hepatitis B vaccine availability
13 October 2017
GSK is currently experiencing an on-going supply constraint of Engerix-B Adult dose (hepatitis B surface antigen recombinant (yeast) vaccine) in Australia. Production is now back to normal, however it will take time to re-build capacity.
Due to a reassessment of the number of doses required for government programs, a limited number of Engerix-B Adult doses were made available to pharmacies and healthcare clinics this week. We expect these supplies to be short-term and at this stage we are unable to confirm when we will return to normal supply of Engerix-B Adult.
We are currently experiencing an intermittent supply constraint of Engerix-B paediatric dose for the private market. We expect to return to supply by the end of 2017.
Supply of GSK vaccines containing hepatitis B to government programs is not impacted.
We are currently experiencing a supply constraint of Twinrix Junior (combined hepatitis A and hepatitis B vaccine) due to the current high demand for hepatitis B-containing vaccines in Australia. We anticipate Twinrix Junior to be back in stock by end November 2017.
Twinrix Adult (combined hepatitis A and B vaccine) is now back in stock following a recent supply constraint.
We understand that these stock-outs may be distressing for those who are not covered by government programs and who may be required to vaccinate themselves for occupational reasons or because they are planning on travelling to hepatitis-affected areas.
Please visit the TGA website for ongoing updates to supply.
For more information, please contact GSK medical information on 1800 033 109.